Research Analysts Issue Forecasts for UBX Q1 Earnings

Posted by Caroline Horne on Mar 11th, 2025

Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) – Equities researchers at HC Wainwright issued their Q1 2025 earnings estimates for Unity Biotechnology in a research report issued to clients and investors on Monday, March 10th. HC Wainwright analyst M. Caufield expects that the company will post earnings per share of ($0.43) for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Unity Biotechnology’s Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS and FY2029 earnings at $0.88 EPS.

Separately, Chardan Capital reiterated a “buy” rating and set a $6.00 price objective on shares of Unity Biotechnology in a research note on Monday.

View Our Latest Analysis on UBX

Unity Biotechnology Stock Down 4.8 %

UBX opened at $1.60 on Tuesday. The firm has a market cap of $26.96 million, a price-to-earnings ratio of -1.22 and a beta of 1.02. Unity Biotechnology has a fifty-two week low of $0.94 and a fifty-two week high of $3.10. The company’s 50-day moving average price is $1.84 and its 200 day moving average price is $1.51.

Institutional Investors Weigh In On Unity Biotechnology

An institutional investor recently raised its position in Unity Biotechnology stock. Bridgeway Capital Management LLC raised its holdings in shares of Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) by 100.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 50,000 shares of the company’s stock after buying an additional 25,000 shares during the period. Bridgeway Capital Management LLC owned about 0.30% of Unity Biotechnology worth $49,000 as of its most recent SEC filing. Institutional investors own 29.49% of the company’s stock.

Unity Biotechnology Company Profile

(Get Free Report)

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.